

# PREFACE

---

A precise tuning of cell replication is mandatory for organismic and cellular homeostasis. Indeed, numerous aspects of human pathology can be thought of as malfunctions of the cell cycle. Cancer is unquestionably among these.

In the past, an accelerated mitotic rate traditionally has been considered to be a major characteristic of either benign or malignant neoplastic diseases. For this reason, cancer growth historically has been considered the epitomy of a disease caused by loss of control of the strategies that regulate the cell cycle. Although the complex and intricate mechanisms that drive malignant transformation are now better understood, nonprogrammed cellular replication still plays a key role in the theoretical schemes we use to understand, prevent, diagnose, and cure cancer.

Modern medicine now moves swiftly toward novel, and previously unsuspected, fields. The molecular approach to disease is ultimately providing a tremendous amount of knowledge that continuously produces revolutionary changes in our abilities to diagnose and cure most diseases. In this exciting scenario, where health care professionals, as well as graduate and medical students, are continuously asked to deal with radically innovative approaches, the role of the scientific literature is to provide constantly up-to-date information on the many recent advances in molecular medicine. In addition, this information should be communicated in a way that is user friendly and comprehensible.

*Cell Cycle Inhibitors in Cancer Therapy: Current Strategies* has been conceived as a scholarly book with the aim to provide state-of-the-art information about the molecules involved in cell cycle control. Such a book will deliver, in a clear language, fundamental information derived from the basic sciences to the medical community, where it can have a direct impact on diagnostics, prognostics, and therapeutics.

We feel there is a tremendous need for such a book as this, which is designed to educate physicians in cell cycle and cell growth control. In effect, *Cell Cycle Inhibitors in Cancer Therapy: Current Strategies* will bring current findings from the research laboratory directly into clinical practice. Finally, we also aim to provide an opportunity for feedback in which high-level clinical practice can stimulate basic science investigators to develop new insight into the many diseases that still constitute difficult medical problems.

Each thematic issue in *Cell Cycle Inhibitors in Cancer Therapy* is therefore designed to provide the latest research information and demonstrate its clinical relevance to our understanding of many of the most prevalent diseases afflicting our society today.

*Antonio Giordano, MD, PhD*

*Kenneth J. Soprano, PhD*

# 2

---

## p27, A Prognostic Indicator Reflecting ...?

---

*Andrew Koff, PhD*

### CONTENTS

SUMMARY

CHANGES IN p27 ACTIVITY/ABUNDANCE ARE PROGNOSTIC  
IN MANY TUMORS

TUMORS ARE THE SUM OF PROLIFERATION AND OTHER CHANGES  
IN THE CELL

HOW CHANGES IN CELL CYCLE REGULATORS MIGHT IMPACT  
TUMOR GROWTH

p27 AS A PROGNOSTIC INDICATOR: A CELL REMOVED  
FROM THE CONSEQUENCE OF ANTI-MITOGENIC SIGNALING

CONCLUSION

ACKNOWLEDGMENTS

REFERENCES

---

### 1. SUMMARY

Over the last five years, the expression of p27kip1, a cyclin-dependent kinase inhibitor, has proved to be a strong prognostic indicator for long-term survival of patients with tumors of the colon, breast, prostate, lung, pituitary, and many other tissues. Tumors arising in these organs that were not expressing p27 protein tended to be more aggressive and patients had a poorer clinical outcome. However, it is not clear why p27 was such a strong prognostic indicator in multiple tissues. Furthermore, before p27 is brought into widespread clinical use, prospective studies will be required to validate, in advance, a clinical course or response to therapy. Without the essential knowledge of what low p27 prognosticates, vis a vis the evolution of the tumor, validation will be difficult. Because there is no possibility of determining directly how low p27 expression facilitates tumor development in humans, we have turned to developing mouse models.

*From: Cancer Drug Discovery and Development:*

*Cell Cycle Inhibitors in Cancer Therapy: Current Strategies*

Edited by: A. Giordano and K. J. Soprano © Humana Press Inc., Totowa, NJ

However, we had to first ask the following questions: Does p27 deficiency contribute to tumor development in the mouse? If p27 deficiency contributed to tumor development, does it mimic the human condition, i.e., were tumors more aggressive? Then, if they were more aggressive, what was the mechanism underlying this? Before we begin to discuss these issues, I apologize to the many investigators whose work will be either uncited or cited only by review.


## 2. CHANGES IN p27 ACTIVITY/ABUNDANCE ARE PROGNOSTIC IN MANY TUMORS

The diagnosis of tumor stage and grade is quite subjective and largely depends on the experience of the pathologist with that specific lesion. Even among experienced pathologists, there are disagreements about clinical stage and grade. The intermediate tumors, those that are clearly more advanced than just hyperplasia but not yet obviously aggressive, present a substantial problem. Because treatment is based on the severity of the disease and the likelihood of its progression to a more severe disease, it is important to remove the ambiguity surrounding diagnosis and prognosis. Well-developed and well-understood molecular markers of disease stage and prognosis will succeed in this endeavor.

Over the last five years the expression of p27kip1, as determined by immunohistochemistry, proved to be a strong prognostic indicator of patient survival of tumors of the colon, breast, prostate, lung, pituitary, bladder, and glioma (reviewed by 1–4). Generally, tumors where low p27 expression was prognostic for severity were of intermediate grade. However, there were exceptions. For example, in Burkitt's lymphoma, increased p27 was associated with increased aggressiveness (5,6). Furthermore, cytosolic localization was observed in ovarian cancers of low malignant potential (7) and Barrett's associated adenocarcinoma (8). While these differences are organ/tumor type specific, they probably underlie the complexity of the regulation of p27 abundance (Fig. 1).

Stabilization of p27 in Burkitt's lymphoma was associated with an increase in cyclin D3 (5,6), which is consistent with the inactivation of p27 by sequestration as originally proposed (9,10) and the observation that myc induced accumulation of D-type cyclins leads to p27 sequestration (11). However, the mechanism by which cyclin D3-cdk association stabilizes p27 remains to be determined—does it block the phosphorylation of p27 on T187 preventing ubiquitin-dependent protein degradation, or does it block the interaction of p27 with the skp2-containing E3?

Cytosolic localization of p27 was observed in BAA (8) and ovarian tumors of low malignant potential (LMP) (7), as well as in a diverse number of sarcomas (P. Capodiceci, C. Cordon-Cardo, AK, unpublished data), and even in a 3T3 cell line (12). However, the molecular mechanism remains a mystery. Candidate proteins that might affect p27 localization and that could be mutated in human tumors abound. These include jab1 (13), Nup50 (14), and TSC2 (15).



**Fig. 1.** Processes that regulate the activity and/or abundance of p27kip1. Current investigations are focused on the elucidation of the molecules involved in each of the processes, and the biologic significance of any one of them has not been determined.

The mechanisms leading to the lack of p27 staining are unclear. The absence of p27 protein has rarely, if ever, been attributed to loss of the chromosomal location of the gene (12p13; 16–18), nor has the absence of protein been well-correlated with loss of mRNA (1–4). However, recent evidence from studies on carcinogen-induced tumor development in p27<sup>+/-</sup> mice (19,20), and in tumor progression in p27<sup>+/-</sup> mice intercrossed with Rb<sup>+/-</sup> mice (21) indicated that gene dosage was an important factor. Thus, unlike many genes that require LOH to be implicated as encoding tumor suppressors, p27 is haploinsufficient, and the conclusion that mRNA does not change may need to be re-evaluated keeping in mind that a 50% reduction may not have been readily determined by the most widely used techniques.

On the other hand, it is generally accepted that the inability to detect p27 is due to post-transcriptional changes in protein abundance, and in some cases, it has been suggested to be due to increased ubiquitin-dependent proteolysis (22–25). The strength of this conviction is apparent in the sense that reviews often offer no other alternative (1–4). However, the data supporting this conclusion was derived from experiments generating protein extracts from tumor samples and measuring p27 ubiquitination (23,24) or the loss of protein (25,26). This only allows a comparison of proteolytic activity in tumors to that seen in normal tissues. Because p27 degradation is associated with commitment to the cell cycle and entry into S-phase, wouldn't tumor extracts have an increased amount of activity? To overcome this concern, there are a number of studies showing that p27 expression in a tumor was not correlated with proliferation as measured by either Ki67 or MIB reactivity (for example *see refs. 27–29*) and that these markers together may be more informative than either alone. This reduced the possibility

that the prognostic significance of p27 would be associated solely with proliferation, but it does not indicate that proteolysis is the reason for low p27 expression.

Tumors arise as a consequence of cells inappropriately executing the decision to proliferate or withdraw from the cell cycle, they are not simply a decision to continue through the cell cycle. The regulation of p27 abundance between cycling and noncycling states is at the level of translation (30,31). As most cells in a tumor are not proliferating, at least as judged by Ki67 or MIB staining, they are not in the cell cycle, but rather may be in the transition of  $G_0$ -to- $G_1$ . A molecular understanding of the mechanisms regulating translational control of p27 mRNA is only now being elucidated (32; A. Vidal, S. Millard, AK, unpublished data).

Perhaps when our understanding of the molecular mechanisms regulating p27 abundance is complete, or better defined than the current synthesis, degradation, and location, we would understand what the loss of p27 represents. Nevertheless, even if we do not know the mechanism that accounts for the loss of p27, a reduction in the amount of functional nuclear p27 protein is prognostic.

### 3. TUMORS ARE THE SUM OF PROLIFERATION AND OTHER CHANGES IN THE CELL

Recently, reviews on the changes that occur during progression from normal cell to tumor mass were scribed by Hanahan and Weinberg (33). There is very little to add to this, however, it is important for this discussion to review some of the landmarks of tumor development. First, cells must be proliferating. Second, the proliferating cell must not be undergoing apoptosis. Third, the proliferating and living cell must suspend or bypass mortality controls. Of course, even given all these changes, a tumor does not develop in a homogenous environment like a tissue-culture dish, rather it develops in an organism and is affected by its interactions with other cells and on environmental factors. Thus, tumors must induce angiogenesis, and tumor cells often alter their interaction with neighboring cells, alleviating the ability of normal cells to maintain the tissue in a clear, but as of yet molecularly undefined, homeostatic state. Finally, tumor cells that have migrated to distant site must also evolve mechanisms of coping in these strange and often hostile environments.

Not all tumors have the need for angiogenesis or develop metastatic potential; however, all undergo changes in proliferation, apoptosis, and senescence. As we are focusing on p27 and the role that it might play in tumor development, it is helpful to consider how cells move from quiescence into the cycle, and back again.

The effect of mitogenic and anti-mitogenic signals on progression through  $G_1$  phase, and the choice between either commitment to the cell cycle and eventual DNA replication or withdrawal from the cell cycle and perhaps acquisition of a differentiated phenotype, is made by controlling the activation status of the

cyclin-dependent kinases. Entry into S-phase requires the activation of two cyclin-dependent kinases, cdk4 and cdk2, which participate together in the inactivation of Rb and the induction of E2F-dependent transcription (34). Although the activation of these kinases is necessary for S-phase entry, it is important to note that there is no evidence in primary cultures of mammalian cells to suggest that this is sufficient to account for all the functions of mitogens required for S-phase entry. Some targets of the cyclin-cdk complexes include pocket-proteins, such as Rb; the cdk inhibitors, such as p27 (35–40); and molecularly defined targets within the centrosome (41). The consequence of target phosphorylation is quite varied. Rb phosphorylation alters gene transcription through changes in HDAC-association and E2F1 association (42). p27 phosphorylation alters its stability. The role of phosphorylation in the centrosome is unclear.

Mitogenic signals, often through the RTKs, induce the synthesis of cyclin D1, inhibit the degradation of cyclin D1, and foster the assembly of cyclin D1 with cdk4 (43–45). Additionally, mitogens can suppress the translation of p27 (30). With an increase in steady-state accumulation of cyclin D-cdk4, the availability of p27 to bind to cyclin E-cdk2 is limited, and thus cyclin E-cdk2 activity could begin to accumulate (10). Once cyclin E-cdk2 accumulates it phosphorylates p27 and initiates ubiquitin-dependent degradation of the protein (35–38,40). This appears to be sufficient to allow for an irreversible commitment to cdk activation in the presence of mitogen.

Anti-mitogenic signals can impact the decision to proliferate by directly increasing the amount of Ink4-type inhibitors. For example, transforming growth factor- $\beta$  (TGF- $\beta$ ) can induce p15 accumulation, p15 complexes with cdk4 preventing the formation of cyclin D-cdk4 complexes. This prevents sequestration of p27 and the amount of p27 will be sufficient to inhibit cyclin E-cdk2 (46). Likewise, antimitogenic signals can directly induce p27 translation by interfering with the rho-dependent mitogenic signal-transduction pathways that suppress it (A. Vidal, S. Millard, AK, unpublished data). In both examples, the anti-mitogenic signal would antagonize the mitogenic signal; however, the final decision would depend on the equilibrium established between cyclin D-cdk4/p27 and cyclin E-cdk2.

There are a number of cdk inhibitors akin to p15 and p27, the Ink4 class (p15, p16, p18, p19) and the Kip class (p21, p27, p57), respectively. These proteins are expressed in a cell-type specific manner, and it is generally assumed that they carry out similar roles in mediating growth arrest. However, if that was true, then one would expect that the individual cki-deficient mice would have quite similar phenotypes, i.e., problems in the differentiation of cells that express that particular cki, but this does not appear to be the case (47). The reasons for this are not clear; however, there is cell-type and signal specificity to their accumulation and function in promoting growth arrest. There may be additional functions in differentiated cells, or as regulators of growth arrest in response to DNA damage or

nucleotide pool perturbation, or in the assembly of cyclin D-cdk complexes (48,49).


#### 4. HOW CHANGES IN CELL CYCLE REGULATORS MIGHT IMPACT TUMOR GROWTH

For a number of years we have known that the length of time that a cell spends between mitosis and DNA replication can affect its response to the signals that ultimately control its proliferative fate. This was first shown in the response of the simple yeast, *Saccharomyces cerevisiae*, to mating pheromones and was instrumental in uncovering *cln3* (50,51). Cancer is a disease where the cell has reduced its dependency on mitogenic signals and no longer responds correctly to anti-mitogenic signals. A few examples from an extensive literature of many mammalian cell types serve to illustrate the fact that  $G_1$  duration affects response: the overexpression of specific D-type cyclins can prevent granulocytic (52) or muscle (53) differentiation. Cyclin overexpression in fibroblasts will accelerate S-phase entry, but will not prevent growth arrest in response to contact inhibition or completely abolish the need for mitogen. Enforced expression of cdk inhibitors, such as p21 can induce muscle (54) or myeloid (55) differentiation. In some cases there is no differentiative effect, only a proliferative one. For example, expression of p27 in primary rat oligodendrocyte precursor cells leads to growth arrest but not differentiation (56). Thus we can conclude that mutations that affect  $G_1$ -duration have a phenotype similar to one that would affect a growth inhibitory signaling pathway. However, these were all in single cell organisms, explanted cells, or cells grown in culture. Is the same true in a multi-cellular organism?

Mouse genetics has made it possible to examine what overexpression of a cyclin, mutation of a cdk, the absence of a cdk inhibitor, or the mutation of proteins that regulate cdk activity (i.e., cyclin D<sub>1</sub>, cyclin E, cdc25, or cdc37), do with regard to tumor development, both spontaneous and carcinogen-induced. There are a large number of these reports on a wide variety of tissues (57–75). The phenotypes of the different cdk inhibitors are discussed individually and have been reviewed (47,76). The phenotypes of the cdk4R24C mutation and the cdk4 knock-out are described in the appropriate references (77,78). Overall, however, individual changes in cdk activity had a relatively modest effect. That might be due to the necessity of activating two cdk's, cdk4/6 and cdk2, to drive cells into S-phase (79,80), but even that is not entirely clear, as the activation of cyclin E-cdk2 should bypass the need for cdk4/6 expression by the current model (Fig. 2) and the observations made when cyclin E was knocked-in to the cyclin D<sub>1</sub> locus (81).

Another interpretation is that mutation of the cell cycle, specifically with respects to the proliferation of tumor cells, is kept innocuous by the homeostasis provided by an animal. Proliferating, oncogenically activated cells may be





**Fig. 2.** Cyclin D-cdk complexes and p27 conspire to regulate cyclin E-cdk2. The decision to commit to S-phase correlates well with the activation of cyclin E-cdk2 kinase. Once activated, cyclin E-cdk2 kinase, insures that a strong positive feedback loop is initiated that leads to the increase of cyclin E mRNA, through further inactivation of the Rb-E2F complex, and the elimination of p27kip1, through ubiquitin-dependent proteolysis. Cyclin D-cdk complexes mediate the passage of mitogenic signals to cyclin E-cdk2 through their effects on Rb-E2F complex, and anti-mitogenic signals through their effects on p27.

undergoing apoptosis or senescence continually in the animal. In contrast to the cell cycle changes, when mice were engineered to overexpress or to express mutated forms of many molecules upstream of the cell cycle, i.e., ras, myc, or the her2 receptor, they were obviously tumor prone. Each of these molecules has effects on cell cycle regulators, but also affect proteins that participate in apoptosis and senescence. For example, growth factor cytokines, such as IL-2 (82) or c-kit (83), acting through their receptors, often tyrosine kinases, have roles regulating cell proliferation and cell survival, often mediated by interactions through the ras- and PI3-kinase signaling pathways, respectively (84,85a). However, activated ras will induce senescence, presumably through Arf and p21 (86–88). Ras will also intersect the cell cycle: through raf controlling the abundance of the cyclin D-cdk4 complex (43), and through rho controlling the abundance of p27 (A. Vidal, S. Millard, AK, unpublished data). PI3 kinase suppresses apoptosis by activating Akt (84). PI3 kinase activity also can regulate p27 abundance (85b). Additionally, the proliferating cell normally induces a p53 response, which is implicated in apoptosis and/or cell cycle arrest (86–89). The dual nature of p53 rests, at least in part, on its ability to induce p21 (88,90) and bax (91), a suppressor of proliferation and an inducer of apoptosis, respectively. Of course, apoptosis and growth arrest can also be p53-independent (92–95).

One way of interpreting this cornucopia of data is that changes in the cell cycle are associated with abnormal proliferation, but are not sufficient to cause abnormal proliferation. Nevertheless, changes in these regulators specifically impact

on the ability of the cell to respond to anti-mitogenic signals. Consistent with this possibility, the tumor phenotypes occurring in these mice expressing *myc* can be enhanced by overexpression of cyclin D<sub>1</sub> (63,96). Those expressing *ras* can cooperate with cyclin E (61). Keratinocytes lacking p21 and expressing oncogenic *ras* form aggressive tumors in nude mice, more so than if they lacked p27 or were wild-type (97). Furthermore, mutation of *cdk4* makes cells refractory to the actions of Ink-class inhibitors and the overexpression of cyclins would titrate Kip-class inhibitors. This would also seem to be consistent with the finding that only a few mutants in the cell cycle regulators gave rise to “cancer-like” phenotypes. Specifically those in p27-deficient mice, p18-deficient mice, Ink4a-deficient mice, and E2F1-deficient mice were informative, displaying tumor growth properties. Both E2F1 and p27 (see below) are implicated in regulating the transition between cycling and noncycling cells.

However, a word about the Ink4a locus, as this may be due to a non-cell cycle effect. The Ink4a locus is incredibly complex, It encodes both the *cdk4* binding protein, p16, and an alternative reading frame, p19Arf1, which share a second exon and have alternative first exons (98). Deletions often, but not always, remove both reading frames (99). Arf1 interacts with and negatively regulates the p53-mdm2 pathway and *myc* participates in this process, albeit there is still some disagreement over the exact nature of these interactions (88,100–104). Thus mutation in a single locus would affect both the Rb and p53 pathways and has brought into question what the role of p16 deletion in human tumors really is. At this time, this question is unanswered. There are mutations in the p16 ORF identified in tumors that do not affect the p19 ORF, at least by sequence analysis, suggesting that p16 may be a tumor suppressor. However, in mice, the p19Arf1 deletion fully recapitulates the growth and transformation properties of cells and the tumor development property of mice observed with the p16<sup>-</sup>/p19<sup>-</sup> mouse (the original Ink4a deletion) (105–107). The rest of this review will studiously ignore the Arf complexity as this has been described recently (108,109).

Consequently, I would raise the proposal that many of the mutations in cell cycle regulators do not drive cell proliferation, but rather make proliferating cells refractory to the consequence of the signals telling them to stop. The goal then became a direct test of the hypothesis, specifically in relationship to p27, rather than culling the data for the consistent observations.

## 5. p27 AS A PROGNOSTIC INDICATOR: A CELL REMOVED FROM THE CONSEQUENCE OF ANTI-MITOGENIC SIGNALING

The phenotype of p27 deficient mice was quite striking (*110*). Our mice expressed an amino truncated protein ( $\Delta 51$ , deleted amino acids 1-51) that failed to bind and inactivate cdks, and two other groups created nullizygous mice (*111,112*). These lines displayed identical phenotypes. Although p18 deficiency can recapitulate some of the phenotypes below, it appears to be more dependent on strain background (*79,113*). The mice were larger than their wild-type littermates, had no measurable increase in the serum level of growth hormone (GH), insulin-like growth hormone (IGF-1), or IGF-2, and there was an increase in the S-phase fraction of cells in organs in which proliferation was occurring, such as thymus. However, there were very few discernable developmental defects associated with increased proliferation in p27<sup>-/-</sup> mice except for deafness (*114,115*) and female infertility (*116*). These data suggested that p27 was involved in the regulation of cell proliferation in many tissues, but did not directly address how.

Evidence from a number of laboratories suggested that p27 was an input for anti-mitogenic differentiation inducing signals, transducing these to the core cell cycle component, cdk2. This was most clearly demonstrated in our studies of the growth and differentiation properties of oligodendrocyte precursor cells isolated from the brain cortex of neonatal mice (*117-119*), and the granulosa-to-luteal cell transition following hormone induced ovulation (*116*). Similar results have been shown in the Organ of Corti and in osteoblasts (*114,115,120*). In each case, a cell-autonomous increase of p27 protein was correlated with differentiation. Thus in cells where it is expressed, p27 clearly has a role in cell cycle withdrawal induced by differentiation signals. The defects we and others reported in the withdrawal program of p27-deficient cells may have been due to a direct response altering their ability to interpret the anti-mitogenic signals, or an indirect response, i.e., these p27<sup>-/-</sup> cells may have a shorter G<sub>1</sub> period. On this note, although p27 deficiency does not alter G<sub>1</sub> duration in mouse embryo fibroblasts, it has not been examined in any of the cell types above.


As might be expected from the model that cell cycle mutation alleviates cellular response to anti-mitogenic signals, but does not promote proliferation, p27 deficient mice also developed a number of spontaneous abnormal growths—very low grade tumors. These mice spontaneously develop benign prostatic hyperplasia (*121*), low-grade C-cell carcinoma of the thyroid (*21*), and a pituitary intermediate lobe hyperplasia or adenoma (*21,110-112*). Additionally, carcinogens were able to induce tumor development more efficiently in knock-out and heterozygous mice than in wild-type counterparts (*19,20*). However, it should be noted that heterozygous mice did not spontaneously develop tumors suggesting that haploinsufficiency at this locus is enough to exacerbate a tumorigenic event, but by itself is not tumorigenic.

Now, in order to test the hypothesis that cell cycle regulators, and p27 specifically, might act to prevent anti-mitogenic response of developing tumor cells, we set out to create a mouse model. Our choice to couple the Rb<sup>+/-</sup> mouse to a p27<sup>-/-</sup> background seemed reasonable as much was understood about tumor development in the Rb<sup>+/-</sup> mouse and the tissues affected were similar to that of the p27<sup>-/-</sup> mouse. Furthermore, if one had to speculate how an oncogenic event would affect cell proliferation, one needs only examine the linkage between ras and Rb. Thus, we speculated that loss of heterozygosity at the Rb locus would provide the oncogenic event and allow us to determine if p27-deficiency would increase the aggressiveness of the resulting tumors.

Rb<sup>-/-</sup> mice die between embryonic d 14 and 15, depending on the specific disrupted allele and background of the animals (122–124). Death is associated with apoptosis in neural tissues and a lack of fetal hematopoiesis. Rb<sup>+/-</sup> mice are viable and lead unremarkable lives early in the postnatal period. However, as the animal ages, there is a remarkable incidence of pituitary adenocarcinoma involving the melanotrophs, and C-cell carcinoma of the thyroid (125,126). Remarkably, this is the same tumor spectrum observed in p27<sup>-/-</sup> mice. Not surprisingly, both p27 and Rb protein accumulate in the mouse melanotroph (21,125). The highly aggressive pituitary adenocarcinoma is thought to be responsible for death of these animals at approx 10–14 mo of age, depending again on genetic background and the specific mutant allele of Rb.

The natural history of the pituitary adenocarcinoma arising in the Rb<sup>+/-</sup> animal is quite interesting. All the tumors underwent LOH of the Rb locus. This occurred very early in postnatal development with 94% of the animals having undergone an LOH event by day 90 (125). These Rb<sup>-/-</sup> cells then re-entered the cell cycle, however those cells innervated by the dopaminergic neuron underwent apoptosis. Dopamine is a potent negative growth regulatory signal for the melanotrophs. At some point during the transition from the early proliferates to tumor, the cells acquire a mutation(s) that allows them to develop into an adenocarcinoma. Because these Rb<sup>-/-</sup> melanotrophs retained the dopamine receptor, it suggested that the other mutations either prevented innervation or the death due to the “oncogenic activation” of Rb LOH coupled with innervation. These mutations might alter the dopaminergic neuron interaction or the ability of the dopaminergic neuron to signal effectively. Whatever the cause, these tumors acquired resistance to innervation and proliferated uncontrollably, or perhaps even proliferated in a manner that now prevented their innervation.

The aforementioned possibilities suggested that signals that disrupt proliferation-induced apoptosis might alter the latency period of this tumor. As indicated this could occur either by disruption of the negative regulatory signals controlling proliferation, or an inability to activate the apoptosis inducing machinery (Fig. 3). Three crosses of Rb<sup>+/-</sup> mice to other genotypes led to an exaggeration



**Fig. 3.** Possible ways to overcome oncogene induced apoptosis. Following an oncogenic event and the induction of cell proliferation, the cell will either die or senesce before causing any significant tumor to form (top). However, if the cell mutates such that it cannot recognize negative growth regulatory signals from surrounding cells, or cannot initiate an apoptotic pathway perhaps initiated by these conflicting signals, it will continue to proliferate and eventually form a tumor mass.

of tumor phenotype as measured by the classical criteria of a shorter latency period. These included the crossing onto a p53-deficient background (127), a p21-deficient background (128), or a p27-deficient background (21). Although p53 mutation was observed in the original Rb<sup>+/-</sup> model, the data is consistent with a model wherein the dopaminergic neuron induced death is occurring because of oncogene induced apoptosis, where loss of Rb is the oncogenic event. Likewise, the ability of p21 deficiency to accelerate the tumor may be similar. But what of p27 deficiency?

One possibility is that the loss of p27 prevents the dopaminergic neuron signal from being strong enough to induce p53-dependent apoptosis. In this model, one would have to assume that the cell simply does not recognize the conflict that leads to oncogene-induced apoptosis. However, there is another alternative. The loss of p27 may allow the rate of cell proliferation in the tumor to exceed the rate of apoptosis induced by the dopaminergic neuron. In this scenario, the cells would more rapidly escape the apoptosis-inducing effects of proximity to the neuron. Only now that this model exists can we examine these mechanisms for the aggressiveness associated with low-p27. However, other models are on the horizon. These involve p27 intercrosses to other tumor suppressors such as Pten and inhibin. The findings of these models, with the findings in the Rb model, may shed light on why p27 is a prognostic indicator. Isn't that what it is all about?

## CONCLUSION

The aforementioned arguments are built on many assumptions, many of which run contrary to the general belief. However, what is unarguable is: 1) that p27 is a strong prognostic indicator, 2) that p27 status is not correlated with proliferation, and 3) that p27 participates in the withdrawal of cells from the cell cycle in response to differentiation-inducing signals. Furthermore, mice now exist where the prognostic indication of p27 is recapitulated in cancers: for Rb+/- mice in the pituitary, for Pten+/- mice in the prostate, and for inhibin-/- mice in the gonadal tissues.

What is important now, is to decide why low-p27 is prognostic: does it reflect enhanced mitogenic signals, the escape from anti-mitogenic signals, or an escape from senescence (85). When we answer this question, low-p27 expression could join in the pantheon of useful markers. At this time, the three events all coordinate or impact on many levels, not the least of which is the sacrosanct gate-keeper of cell cycle, pRb. However, extrapolation of the ras-mediated changes espoused by Hanahan and Weinberg (33), would be consistent with the notion that ras = mitogen, low-p27 = anti-mitogen, and p53-mdm2-arf-cyclin D-Rb may be related to apoptosis and senescence and the integration of the three events.

## ACKNOWLEDGMENTS

I wish to thank David Shaffer, Diana Gitig, Anxo Vidal, Michele Park, and Carlos Cordon-Cordo for comments regarding this review. I also thank the members of the Breast Cancer SPORE of Memorial Sloan-Kettering Cancer Center for opinions on the role that loss of p27 might play in human cancers, and the funding for the creation of the Rb-p27 model. Work in the laboratory is supported by grants from the NIH, Pew Foundation, and Irma T. Hirsch Trust.

## REFERENCES

1. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. *Annu Rev Med* 1999;50:401-423.
2. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. *Am J Pathol* 1999;154:313-323.
3. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. *J Cell Physiol* 2000;183:18-27.
4. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. *J Cell Physiol* 2000;183:10-17.
5. Barnouin K, Fredersdorf S, Eddaoudi A, Mittnacht S, Pan LX, Du MQ, Lu X. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. *Oncogene* 1999;18:6388-6397.
6. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde, L, et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. *Blood* 1999;94:765-772.

7. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. *Cancer Res* 1999;59:3790–3794.
8. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. *Cancer Res* 1998;58:1730–1735.
9. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. *Genes Dev* 1994;8:9–22.
10. Soos T J, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, et al. Formation of p27-CDK complexes during the human mitotic cell cycle. *Cell Growth Differ* 1996;7:135–146.
11. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. *EMBO J* 1999;18:5321–5333.
12. Wang G, Miskimins R, Miskimins WK. The cyclin-dependent kinase inhibitor p27Kip1 is localized to the cytosol in Swiss/3T3 cells. *Oncogene* 1999;18:5204–5210.
13. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. *Nature* 1999;398:160–165.
14. Smitherman M, Lee K, Swanger J, Kapur R, Clurman BE. Characterization and targeted disruption of murine nup50, a p27(Kip1)-interacting component of the nuclear pore complex [In Process Citation]. *Mol Cell Biol* 2000;20:5631–5642.
15. Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. *Proc Natl Acad Sci USA* 1998;95:15653–15658.
16. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. *Cancer Res* 1995;55:1211–1214.
17. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. *Cancer Res* 1995;55:1206–1210.
18. Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL, et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. *Cancer Res* 1995;55:1199–1205.
19. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haploinsufficient for tumour suppression. *Nature* 1998;396:177–180.
20. Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ. Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. *Oncogene* 1999;18:4689–4698.
21. Park MS, Rosai J, Nguyen HT, Capodiceci P, Cordon-Cardo C, Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. *Proc Natl Acad Sci USA* 1999;96:6382–6387.
22. Elledge SJ, Harper JW. The role of protein stability in the cell cycle and cancer. *Biochim Biophys Acta* 1998;1377:M61–M70.
23. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. *Science* 1995;269:682–685.
24. Piva R, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, Draetta GF, Schiffer D. Proteasome-dependent degradation of p27/kip1 in gliomas. *J Neuropathol Exp Neurol* 1999;58:691–696.
25. Agus DB, Cordon-Cardo C, Fox W, Drobnyak M, Koff A, Golde D W, Scher HI. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. *J Natl Cancer Inst* 1999;91:1869–1876.
26. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. *Nat Med* 1997;3:231–234.

27. Shamma A, Doki Y, Tsujinaka T, Shiozaki H, Inoue M, Yano M, et al. Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. *Oncology* 2000;58:152–158.
28. Cavalla P, Piva R, Bortolotto S, Grosso R, Cancelli I, Chio A, Schiffer D. p27/kip1 expression in oligodendrogliomas and its possible prognostic role. *Acta Neuropathol (Berl)* 1999;98: 629–634.
29. Palmqvist R, Stenling R, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. *J Pathol* 1999;188:18–23.
30. Agrawal D, Hauser P, McPherson F, Dong F, Garcia A, Pledger WJ. Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. *Mol Cell Biol* 1996;16: 4327–4336.
31. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, and Koff A. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. *J Biol Chem* 1997;272:7093–7098.
32. Millard SS, Vidal A, Markus M, Koff A. A U-Rich Element in the 5' untranslated region is necessary for the translation of p27 mRNA. *Mol Cell Biol* 2000;20:5947–5959.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57–70.
34. Reed SI. Control of the G1/S transition. *Cancer Surv* 1997;29:7–23.
35. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. *Genes Dev* 1999;13:1181–1189.
36. Morisaki H, Fujimoto A, Ando A, Nagata Y, Ikeda K, Nakanishi M. Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2. *Biochem Biophys Res Commun* 1997;240:386–390.
37. Mueller A, Odze R, Jenkins TD, Shahsesfaei A, Nakagawa H, Inomoto T, Rustgi AK. A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. *Cancer Res* 1997;57:5542–5549.
38. Nguyen H, Gitig DM, Koff A. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. *Mol Cell Biol* 1999;19:1190–1201.
39. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. *Genes Dev* 1997;11:1464–1478.
40. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. *EMBO J* 1997;16:5334–5344.
41. Nigg EA, Blangy A, Lane HA. Dynamic changes in nuclear architecture during mitosis: on the role of protein phosphorylation in spindle assembly and chromosome segregation. *Exp Cell Res* 1996;229:174–180.
42. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell* 1999;98:859–869.
43. Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). *Proc Natl Acad Sci USA* 1998;95:1091–1096.
44. Roussel MF, Theodoras AM, Pagano M, Sherr CJ. Rescue of defective mitogenic signaling by D-type cyclins. *Proc Natl Acad Sci USA* 1995;92:6837–6841.
45. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells. *Mol Cell Biol* 1994;14:2066–2076.
46. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. *Genes Dev* 1995;9:1831–1845.
47. Kiyokawa H., Koff A. Roles of cyclin-dependent kinase inhibitors: lessons from knock-out mice. *Curr Topics Microbiol Immunol* 1997;227:105–120.



48. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. *EMBO J* 1999;18:1571–1583.
49. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. *Genes Dev* 1994;8:1750–1758.
50. Cross FR. Cell cycle arrest caused by CLN gene deficiency in *Saccharomyces cerevisiae* resembles START-I arrest and is independent of the mating-pheromone signalling pathway. *Mol Cell Biol* 1990;10:6482–6490.
51. Richardson HE, Wittenberg C, Cross F, Reed SI. An essential G1 function for cyclin-like proteins in yeast. *Cell* 1989;59:1127–1133.
52. Kato JY, Sherr CJ. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. *Proc Natl Acad Sci USA* 1993;90:11513–11517.
53. Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. *Science* 1995;267:1022–1024.
54. Halevy O, Novitsch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. *Science* 1995;267:1018–1021.
55. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. *Genes Dev* 1996;10:142–153.
56. Tikoo R, Osterhout DJ, Casaccia-Bonnel P, Seth P, Koff A, Chao MV. Ectopic expression of p27Kip1 in oligodendrocyte progenitor cells results in cell-cycle growth arrest. *J Neurobiol* 1998;36:431–440.
57. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. *Mol Cell Biol* 1997;17:453–459.
58. Bortner DM, Rosenberg MP. Overexpression of cyclin A in the mammary glands of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis. *Cell Growth Differ* 1995;6:1579–1589.
59. Gomez Lahoz E, Liegeois NJ, Zhang P, Engelman JA, Horner J, Silverman A, et al. Cyclin D- and E-dependent kinases and the p57(KIP2) inhibitor: cooperative interactions in vivo. *Mol Cell Biol* 1999;19:353–363.
60. Jenkins TD, Mueller A, Odze R, Shahsafaei A, Zukerberg LR, Kent R, et al. Cyclin D1 overexpression combined with N-nitrosomethylbenzylamine increases dysplasia and cellular proliferation in murine esophageal squamous epithelium. *Oncogene* 1999;18:59–66.
61. Karsunky H, Geisen C, Schmidt T, Haas K, Zevnik B, Gau E, Moroy T. Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc. *Oncogene* 1999;18:7816–7824.
62. Klug DB, Crouch E, Carter C, Coghlan L, Conti CJ, Richie ER. Transgenic expression of cyclin D1 in thymic epithelial precursors promotes epithelial and T cell development. *J Immunol* 2000;164:1881–1888.
63. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. *EMBO J* 1994a;13:3487–3495.
64. Lovec H, Sewing A, Lucibello FC, Muller R, Moroy T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. *Oncogene* 1994b;9:323–326.
65. Ma ZQ, Chua SS, DeMayo FJ, Tsai SY. Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. *Oncogene* 1999;18:4564–4576.
66. Muller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, et al. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. *Oncogene* 1997;15:2561–2576.
67. Nakagawa H, Wang TC, Zukerberg L, Odze R, Togawa K, May GH, et al. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. *Oncogene* 1997;14:1185–1190.

68. Pierce AM, Fisher SM, Conti CJ, Johnson DG. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. *Oncogene* 1998a;16:1267–1276.
69. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. *Proc Natl Acad Sci USA* 1998b;95:8858–8863.
70. Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, and Johnson DG. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. *Mol Cell Biol* 1999;19:6408–6414.
71. Robles AI, Larcher F, Whalin RB, Murillas R, Richie E, Gimenez-Conti IB, et al. Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. *Proc Natl Acad Sci USA* 1996;93:7634–7638.
72. Rodriguez-Puebla ML, LaCava M, Conti CJ. Cyclin D1 overexpression in mouse epidermis increases cyclin-dependent kinase activity and cell proliferation in vivo but does not affect skin tumor development. *Cell Growth Differ* 1999;10:467–472.
73. Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW. The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. *Mol Cell Biol* 2000;20:4462–4473.
74. Wang D, Russell JL, Johnson DG. E2F4 and E2F1 have similar proliferative properties but different apoptotic and oncogenic properties in vivo. *Mol Cell Biol* 2000;20:3417–3424.
75. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. *Nature* 1994;369:669–671.
76. Vidal A, Koff A. Cell-cycle inhibitors: three families united by a common cause. *Gene* 2000;247:1–15.
77. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, Barbacid M. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. *Nat Genet* 1999;22:44–52.
78. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. *Mol Cell Biol* 1999;19:7011–7019.
79. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. *Genes Dev* 1998;12:2899–2911.
80. Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. *Mol Cell Biol* 1995;15:3463–3469.
81. Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, et al. Rescue of cyclin D1 deficiency by knockin cyclin E. *Cell* 1999;97:767–777.
82. Adachi M, Torigoe T, Takayama S, Imai K. BAG-1 and Bcl-2 in IL-2 signaling. *Leuk Lymphoma* 1998;30:483–491.
83. Besmer P. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. *Curr Opin Cell Biol* 1991;3:939–946.
84. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. *Curr Opin Cell Biol* 1998a;10:262–267.
- 85a. Downward J. Ras signalling and apoptosis. *Curr Opin Genet Dev* 1998b;8:49–54.
- 85b. Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J, et al. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. *J Biol Chem* 2000;275:21960–21968.
- 86a. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. *Cell Mol Life Sci* 1999;55:48–63.
- 86b. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* 1997;88:593–602.
87. Attardi LD, Lowe SW, Brugarolas J, Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. *EMBO J* 1996;15:3702–3712.

87. Vogt M, Haggblom C, Yeargin, J, Christiansen-Weber T, Haas M. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. *Cell Growth Differ* 1998;9:139–146.
88. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. *Nat Cell Biol* 1999;1:20–26.
88. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. *Proc Natl Acad Sci USA* 1999;96:1002–1007.
89. Guillouf C, Grana X, Selvakumaran M, De Luca A, Giordano A, Hoffman B, Liebermann DA. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest. *Blood* 1995;85:2691–2698.
90. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. *Nature* 1995;377:552–557.
91. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. *Proc Natl Acad Sci USA* 1997;94:2345–2349.
92. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R, Wahl GM. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. *Curr Biol* 1998;8:145–155.
93. Corbet SW, Clarke AR, Gledhill S, Wyllie AH. P53-dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells. *Oncogene* 1999; 18: 1537–1544.
94. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 [see comments]. *Cell* 1994;79:329–339.
95. Wyllie FS, Haughton MF, Bond JA, Rowson JM, Jones CJ, Wynford-Thomas D. S phase cell-cycle arrest following DNA damage is independent of the p53/p21(WAF1) signalling pathway. *Oncogene* 1996;12:1077–1182.
96. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. *EMBO J* 1994;13:2124–2130.
97. Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. *Genes Dev* 1996;10:3065–3075.
98. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell* 1995;83:993–1000.
99. Quelle DE, Cheng M, Ashmun RA, Sherr CJ. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. *Proc Natl Acad Sci USA* 1997;94:669–673.
100. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. *Genes Dev* 1999;13:2658–2669.
101. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. *Proc Natl Acad Sci USA* 1998;95:8292–8297.
102. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. *Proc Natl Acad Sci USA* 1999;96:3077–3080.
103. Tao W, Levine AJ. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. *Proc Natl Acad Sci USA* 1999;96:6937–6941.
104. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. *Genes Dev* 1998;12:2424–2433.

105. Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA, Sherr CJ, McKinnon PJ. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. *Cancer Res* 1999a;59:2464–2469.
106. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. *Cancer Res* 1999b;59:2217–2222.
107. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. *Cell* 1997;91:649–659.
108. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. *Genes Dev* 1998;12:2984–2991.
109. Sherr CJ, Weber JD. The ARF/p53 pathway. *Curr Opin Genet Dev* 2000;10:94–99.
110. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). *Cell* 1996;85:721–732.
111. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. *Cell* 1996;85:733–744.
112. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. *Cell* 1996;85:707–720.
113. Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. *EMBO J* 2000;19:3496–3506.
114. Chen P, Segil N. p27(Kip1) links cell proliferation to morphogenesis in the developing organ of Corti. *Development* 1999;126:1581–1590.
115. Lowenheim H, Furness DN, Kil J, Zinn C, Gultig K, Fero ML, et al. Gene disruption of p27(Kip1) allows cell proliferation in the postnatal and adult organ of corti. *Proc Natl Acad Sci USA* 1999;96:4084–4088.
116. Tong W, Kiyokawa H, Soos TJ, Park MS, Soares VC, Manova K, et al. The absence of p27Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa- >luteal transition. *Cell Growth Differ* 1998;9:787–794.
117. Casaccia-Bonnel P, Hardy RJ, Teng KK, Levine JM, Koff A, Chao MV. Loss of p27Kip1 function results in increased proliferative capacity of oligodendrocyte progenitors but unaltered timing of differentiation. *Development* 1999;126:4027–4037.
118. Casaccia-Bonnel P, Tikoo R, Kiyokawa H, Friedrich V Jr, Chao MV, Koff A. Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent kinase inhibitor p27Kip1. *Genes Dev* 1997;11:2335–2346.
119. Durand B, Fero ML, Roberts JM, Raff MC. p27Kip1 alters the response of cells to mitogen and is part of a cell-intrinsic timer that arrests the cell cycle and initiates differentiation. *Curr Biol* 1998;8:431–440.
120. Drissi, H., Hushka, D., Aslam, F., Nguyen, Q., Buffone, E., Koff, A., et al. The cell cycle regulator p27kip1 contributes to growth and differentiation of osteoblasts. *Cancer Res* 1999;59:3705–3711.
121. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. *J Natl Cancer Inst* 1998;90:1284–1291.
122. Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML, et al. Requirement for a functional Rb-1 gene in murine development. *Nature* 1992;359:328–330.
123. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. *Nature* 1992;359:295–300.
124. Lee EY, Chang CY, Hu N, Wang, YC, Lai CC, Herrup K, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. *Nature* 1992;359:288–294.

125. Nikitin A, Lee WH. Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb<sup>+/-</sup> mice. *Genes Dev* 1996;10:1870–1879.
126. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1<sup>(+/-)</sup> mice. *Nat Genet* 1998;18:360–364.
127. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. *Nat Genet* 1994;7:480–484.
128. Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. *J Cell Biol* 1998;141:503–514.

